Membrane Fusion between Retroviral Particles: Host-Range Extension and Vaccine Prospects  by Sparacio, Sandra et al.
p
t
f
p
r
e
t
a
a
e
v
d
h
s
d
Virology 271, 248–252 (2000)
doi:10.1006/viro.2000.0294, available online at http://www.idealibrary.com onRAPID COMMUNICATION
Membrane Fusion between Retroviral Particles: Host-Range Extension and Vaccine Prospects
Sandra Sparacio, Udo Zeilfelder, Tanya Pfeiffer, Tanja Henzler, and Valerie Bosch1
Forschungsschwerpunkt Angewandte Tumorvirologie, F0200, Deutsches Krebsforschungszentrum,
Im Neuenheimer Feld 242, D-69120 Heidelberg, Germany
Received December 6, 1999; returned to author for revision February 7, 2000; accepted March 6, 2000
We have analyzed if different populations of retroviral particles carrying the viral and cellular receptors of membrane
viruses, respectively, are able to specifically fuse with each other. Using the glycoprotein of human immunodeficiency virus
type 1 and its cellular receptor complex, we demonstrate that interviral membrane fusion can, indeed, occur and that the
resultant fused viral structures are able to infect cells and transduce a marker gene. On the one hand, these results have
relevance for the development of vaccine strategies based on fusion-induced conformational epitopes on the viral glyco-
protein. However, in addition to this potential practical application, the results obtained (which were extended to include
analyses with the vesicular stomatitis virus G protein and its cellular receptor) have far-reaching implications for in vivo
situations in which simultaneous infections with different membrane viruses can occur. © 2000 Academic PressKey Words: interviral fusion; host range; human immunodeficiency virus; HIV glycoprotein; vaccine; CD4; CXCR-4; cellular
receptor; VSV-G; transduction.
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bIntroduction. A putative “fusion-competent” whole-cell
immunogen with the potential of eliciting broadly neu-
tralizing HIV antibodies in CD4/CCR5 transgenic mice
has recently been described (1). The relevant immuno-
gen is presumed to consist of HIV Env conformations
transiently arising during fusion between individual cells
expressing CD4/coreceptor and HIV Env, respectively. It
has previously been demonstrated that cellular glyco-
proteins can efficiently be incorporated into the mem-
brane of retroviral and rhabdoviral particles and can
function there to mediate infection of cells carrying the
appropriate viral receptor (2–5). We thus considered the
ossibility that a more potent and cleaner fusion-compe-
ent HIV immunogen may be generated by transient
usion between two different types of subviral HIV-like
articles with incorporated CD4/coreceptor and HIV Env,
espectively. If this were the case, it was of further inter-
st to establish if fused viral structures, carrying more
han one core, were infectious (that is able to transduce
marker gene to target cells). In order to potentially
chieve higher infectivity of fused viral structures, we
xtended these analyses to include the glycoprotein of
esicular stomatitis virus (VSV-G), which is a potent me-
iator of retroviral transduction (6, 7). We demonstrate
ere that specific interretroviral particle membrane fu-
ion can occur, that fused retroviral particles are infec-
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248tious (with increased infectivity mediated by VSV-G), and
that these have the host range of both fusion partners.
On the one hand, these results demonstrate the potential
feasibility of an HIV vaccine strategy employing fixed
preparations of molecularly well-defined HIV-like parti-
cles in the process of membrane fusion. Importantly,
potential interviral fusion in vivo (e.g., in patients infected
ith two enveloped viruses) may have far-reaching con-
equences relevant for disease development and
rogress.
Results and Discussion. The first strategy which we
mployed to analyze membrane fusion between HIV-like
articles is illustrated in Fig. 1A. Particles, with incorpo-
ated CD4 and CXCR-4 and carrying a transducible lu-
iferase reporter gene, are referred to as CD4/CXCR-4
arget particles. Particles with incorporated Wt HIV Env,
ut lacking transducible vector, are referred to as Wt-Env
usion particles. We hypothesized that if membrane fu-
ion between target and fusion particles would occur,
he resultant fused viral structures could be infectious
or, and be able to transduce the luciferase gene to,
D4/CXCR-4-expressing 293T cells.
Target particles were generated by cotransfecting
93T cells with an Env-defective proviral construct,
NL4-3.Luc.R-E- (8), encoding the luciferase gene in-
tead of nef, plus expression vectors for CD4 and
XCR-4, either alone or in combination. It has previously
een shown that CD4 and CXCR-4 can be incorporatednto HIV particles and mediate infectivity into HIV-1-in-
ected cells (5) and we confirmed that our CD4/CXCR-4
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249RAPID COMMUNICATIONtarget particles were infectious for, and efficiently trans-
mitted luciferase activity into, HIV Env-expressing BJAB-
Envi cells (9) (data not shown). In the strategy shown in
Fig. 1A, Wt-Env fusion particles, or mutants thereof, were
generated by coexpressing an Env-defective proviral
plasmid, with a deletion in the packaging signal, with Wt
or mutant HIV Env. Appropriate volumes of culture su-
pernatants, representing equal amounts of target parti-
cles on the one hand and equal amounts of fusion
particles on the other hand, were mixed (at a ratio of 1:1)
and preincubated for 90 min at 37°C to allow potential
fusion to occur (see Materials and Methods). Mixed
supernatants were subsequently applied to CD4/CXCR-
4-expressing 293T cells and 3 days posttransduction, the
luciferase activities in cell lysates were determined.
As shown in Fig. 2A, CD4/CXCR-4 target particles
alone resulted in only very low levels of luciferase activity
after transfer to CD4/CXCR-4-expressing 293T cells.
However, when these CD4/CXCR-4 target particles were
mixed with culture supernatants containing Wt-Env fu-
sion particles, the resultant mixture led to a 30- to 50-fold
increase in transduction of CD4/CXCR-4-expressing
293T cells. No transduction was observed employing
293T cells lacking CD4/CXCR-4. The luciferase values
obtained were, in fact, about 2% of those obtained when
Wt HIV Env itself, instead of CD4/CXCR-4, was directly
incorporated into target particles (Fig. 2A). We consider
this value of 2% to be relatively high. This is because, on
the one hand, the particle concentration in the culture
FIG. 1. Strategies to analyze interretroviral particle fusion and the
infectivities of fused viral structures. (A) Target particles (left), gener-
ated as described under Materials and Methods, carry a genome
encoding a marker luciferase gene (Luc) and have incorporated CD4
and CXCR-4. Fusion particles (middle) lack marker gene and have
incorporated HIV Env. Target particles, fusion particles, or mixtures of
target particles and fusion particles were analyzed as to their ability to
transmit luciferase (luc) activity to indicator CD4/CXCR-4-expressing
293T cells. (B) As in A, but fusion particles have incorporated VSV-G in
addition to HIV Env. The indicator cells are 293T cells, not expressing
CD4/CXCR-4.supernatants is in the range of only 1–5 mg/ml, making it
unlikely that every target particle can fuse with a fusion
C
Hparticle. Additionally, it is unlikely that fused viral struc-
tures are as efficient in mediating luciferase gene trans-
duction as genuine viral particles. Several controls were
performed in order to confirm that the observed trans-
duction was due to a fusion event (and not just a binding
event) requiring all components, namely CD4, CXCR-4,
and Wt HIV Env in a functional form. On the one hand,
CD4 target particles or CXCR-4 target particles, with
incorporated CD4 or CXCR-4 alone, respectively, were
mixed with Wt-Env fusion particles. On the other hand,
EnvFus2 fusion particles, with incorporated nonfusogenic
IV Env with a mutation in the gp41 fusion peptide, were
ixed with CD4/CXCR-4 target particles. All these mix-
ures gave only background levels of transduction. These
esults clearly indicate that specific CD4/CXCR-4/HIV-
nv-dependent interretroviral fusion can occur and that
he resultant fused particles are infectious.
When we initially developed the experimental strategy
llustrated in Fig. 1A, we had considered the possibility
hat the potential transduction by fused particles could
e an inefficient process, and thus difficult to measure,
ince a fraction of the HIV Env would already have
ngaged in membrane fusion with the target particles
nd thus would no longer be available to mediate infec-
ion of cells. Although, as shown in Fig. 2A, this consid-
ration was unwarranted, we concomitantly developed
he alternative strategy illustrated in Fig. 1B, which would
llow us to circumvent this potential problem. In this
trategy, in addition to HIV Env, the fusion particles (now
eferred to as Wt-Env/G fusion particles) have incorpo-
ated VSV-G glycoprotein, which is a potent mediator of
etroviral vector transduction (6, 7). In this situation, after
otential fusion between target and fusion particles,
hich should still be mediated by CD4/CXCR-4 and HIV
nv, the infection of 293T cells (lacking CD4/CXCR-4) and
transduction of the luciferase gene by the fused particles
should be mediated by VSV-G. As shown in Fig. 2B, this
is, in fact, the case and mixtures of CD4/CXCR-4 target
and Wt-Env/G fusion particles resulted in high luciferase
activity in transduced 293T cell lysates. The VSV-G-me-
diated luciferase activities were, in fact, 20–50 times
higher than those obtained with HIV Env (Fig. 2A), con-
sistent with the superior ability of VSV-G to mediate
retroviral transduction as described by others (6, 7). It
was initially a surprising observation that mixtures of
Wt-Env/G fusion particles, or EnvFus2/G fusion particles,
aving incorporated HIV Env mutated within the gp41
usion peptide, plus CD4 target particles having incorpo-
ated CD4 alone, still led to significant transduction of
uciferase (Fig. 2B). The values obtained in several dif-
erent experiments were in the range of 20–50% of the
alues obtained with CD4/CXCR-4 target particles plus
t-Env/G fusion particles. In fact, all further mixtures of
arget and fusion particles (CXCR-4 target particles with
Bind2XCR-4 alone, Env /G fusion particles with defective
IV Env mutated at the CD4 binding site (Fig. 2B), or
v
o
W
H
b
p
i
a
r
p
i
a
l
t
(
E
t
h
o
(
v
t
v
m
i
e
block give the percentage luciferase activity in comparison to that
generated by a mixture of CD4/CXCR-4 target particles and Wt-Env/G
250 RAPID COMMUNICATIONVSV-G alone in fusion particles (not shown)) also re-
sulted in luciferase transduction as long as the fusion
particles contained VSV-G glycoprotein. In these latter
cases, the luciferase values obtained were in the range
of 2–10% of the values obtained with CD4/CXCR-4 target
particles plus Wt-Env/G fusion particles (Fig. 2B). On the
other hand, when VSV-G was absent from fusion parti-
cles, and these were mixed with CD4/CXCR-4 target
particles, only background levels of luciferase transduc-
tion into 293T cells were observed. We interpret these
positive but clearly reduced luciferase transduction val-
ues, in the absence of CD4/CXCR-4/HIV-Env-mediated
fusion, but in the presence of VSV-G, to be the result of
particle fusion mediated by VSV-G on fusion particles
and VSV-G cellular receptor which has been incorpo-
rated into target particles. This would be despite the fact
that VSV-G normally requires low pH in the cellular en-
dosome, after receptor-mediated uptake, to trigger mem-
brane fusion. The VSV-G cellular receptor has been
shown to include phospholipid components (10, 11),
which would also be incorporated into virus-like parti-
cles. In those situations in which CD4 and HIV Env can
bind to each other but not fuse (CD4 target particles,
EnvFus2/G fusion particles), the luciferase transduction
alues of mixed particles are significantly higher (20–50%
f the values obtained with CD4/CXCR-4 target plus
t-Env/G fusion particles) than in the absence of CD4/
IV Env binding (2–10%). This is presumably due to the
inding between CD4 and HIV Env leading to a closer
roximity between target and fusion particles and allow-
ng more efficient membrane fusion mediated by VSV-G
nd its cellular receptor. Last, as a further proof of the
ole of CD4 in mediating binding and fusion between
articles, the presence of CD4 monoclonal antibody dur-
ng the incubation between CD4/CXCR-4 target particles
nd Wt-Env/G fusion particles very significantly inhibited
uciferase transduction (Fig. 2C).
The results of this latter set of experiments confirm, on
he one hand, the results obtained using the first strategy
Figs. 1A and 2A), namely that specific CD4/CXCR-4/HIV-
nv-dependent interretroviral fusion can occur and that
he resultant fused particles are infectious. The results,
owever, further indicate that, even in the absence of
verexpression, cellular receptors for membrane viruses
VSV as an example) can be incorporated into foreign
irus particles in amounts sufficient to mediate interpar-
icle fusion with virus particles carrying the respective
iral receptor. Thus, depending on the nature of the
embrane virus, the tissue distribution of its cellular
fusion particles. (C) Inhibition of transduction by monoclonal antibody
against CD4. Mixtures of CD4/CXCR-4 target particles and Wt-Env/G
fusion particles were either untreated (no inhibitor) or preincubated
with irrelevant antibody (EGFR) or with antibody against CD4 (SIM-2 1FIG. 2. Luciferase gene transduction after interviral particle fusion
mediated by CD4/CXCR-4 and HIV Env. (A) HIV Env-mediated gene
transduction. The glycoprotein compositions of the respective target
and fusion particles, which were premixed prior to application to
CD4/CXCR-4-expressing 293T cells, and the resulting luciferase activ-
ities (total activities per culture given on the y axis) in lysates of
transduced cells are given for a representative experiment (from three
independent experiments). The numbers above each block give the
percentage luciferase activity in comparison to that generated by a
mixture of CD4/CXCR-4 target particles and Wt-Env fusion particles. (B)
VSV-G-mediated gene transduction. The glycoprotein compositions of
the respective target and fusion particles, which were premixed prior to
application to 293T cells (not expressing CD4/CXCR-4) and the result-
ing luciferase activities (total activities per culture given on the y axis)
n lysates of transduced 293T cells are given for a representative
xperiment. G denotes VSV-G glycoprotein. The numbers above eachSIM-4). The numbers above each block give the percentage luciferase
activity in comparison to that of the untreated sample.
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251RAPID COMMUNICATIONreceptor, and the availability of this molecule for incor-
poration into particles, interviral membrane fusion may
be a previously unrecognized in vivo process (not achiev-
able by simple pseudotyping) by which the genomes of
membrane viruses can target cells lacking appropriate
cellular receptor. A theoretical scenario describing such
a situation is shown in Fig. 3. In this situation, membrane
virus X, released from cells carrying cellular receptor for
both virus X and virus Y (but intracellularly blocked for
replication of virus Y) would incorporate cellular receptor
for virus Y (YR) and thus fuse with virus Y itself (produced
n permissive cells). The resulting fused viral structures
ould then be able to transfer the genome of virus Y to
urther cells lacking YR but carrying the cellular receptor
for virus X (XR). Depending on the viruses and target cells
nvolved, this could have far-reaching consequences for
he infected organism, e.g., stable production of virus Y
ithin the animal from a hitherto unrecognized cell res-
rvoir.
As already mentioned, based on the data reported by
aCasse et al. (1), the results obtained here in principle
upport the view that fixed preparations of well-defined,
using CD4/CXCR-4 target and Wt-Env fusion particles
ay represent a potential HIV vaccine. In fact, the same
trategy could be applicable to the glycoproteins of other
athogenic membrane viruses and their cellular recep-
ors (e.g., hepatitis C virus). Further experiments will now
im, on the one hand, at optimizing fusion (e.g., by vary-
ng the particle concentration or the ratio of target and
usion particles). On the other hand, in order to analyze
mmune (and possibly protective) responses, prepara-
ions of noninfectious, subviral HIV-like target and fusion
articles, paraformaldehyde fixed (at different time
oints) in the process of membrane fusion and concen-
rated by ultracentrifugation, should be inoculated into
usceptible animal models.
Materials and Methods. Constructs employed. pNL4-
.Luc.R-E-, an env-defective HIV-1 proviral construct, en-
oding luciferase instead of nef (8), was used to gener-
FIG. 3. Targeting of viral genome to cells lacking cellular receptor as
X (left) carries cellular receptors for viruses X and Y (XR and YR, respectiv
o replicate virus Y. Released virus X, with incorporated YR, can fuse w
viral structure is able to transfer the genome of virus Y, via viral recepte target particles. PSG5-CD4-GpI was a kind gift from
arc Alizon (INSERM, Paris). It encodes GPI-anchored
a
cuman CD4 (referred to in this paper as CD4) with the
xtracellular domain of CD4 and the C-terminal region of
D55. It was employed since, in our hands, this con-
truct (plus CXCR-4) results in two to three times better
nfection of HIV-Env-expressing cells than Wt CD4 (data
ot shown). Expression of CXCR-4 was achieved employ-
ng pc.Fusin (12) (for target particles) or pBABE.Fusin (12)
to generate CD4/CXCR-4-expressing 293T cells, see be-
ow). The proviral construct, pNL4-3DCDEnv3, based on
NL4-3 (13), contains a frame-shift mutation at the be-
inning of the env gene (3) and a deletion in the pack-
ging signal (14). It was employed to generate fusion
articles. pLbAcenv/neo (referred to here as pHIV-Env)
ncodes Wt HIV Env (15). The derivatives referred to here
s HIV-EnvFus2 and HIV-EnvBind2 carry mutations within
he fusion peptide (gp41.2) (16) and CD4 binding site (17),
respectively. pEx-VSV-G encodes the vesicular stomatitis
virus G glycoprotein.
Generation of Target and Fusion Particles. pNL4-
3.Luc.R-E-, plus PSG5-CD4-GpI and pc.Fusin singly and
in combination (to generate target particles), or pNL4-
3DCDEnv3 plus Wt or mutated versions of pHIV-Env in
the presence or absence of pEx-VSV-G (to generate fu-
sion particles), were cotransfected into 293T cells using
standard calcium phosphate procedures. Forty-eight
hours posttransfection, the amounts of released parti-
cles were quantitated by ELISA for HIV-1-CA (Innogenet-
ics, Belgium). Expression of CD4, CXCR-4 (employing
CXCR-4 monoclonal antibody (12G5) (18)), HIV Env, and
VSV-G (antiserum from Lee Biomolecular, San Diego)
were confirmed by indirect immunofluorescence analy-
ses employing respective specific antisera as previously
described (9, 15) (data not shown). Appropriate volumes
of culture supernatants, filtered through a 0.45-mm filter,
nd representing equal amounts of different target par-
icles on the one hand and equal amounts of different
usion particles on the other hand were adjusted to 8 mM
olybrene, mixed (at a ratio of 1:1) in a final volume of 2
l and incubated for 90 min at 37°C, 5% CO2, before
t of specific interviral fusion. The hypothetical producer cell, A, for virus
t (in order to distinguish this phenomenon from pseudotyping) is unable
Y, produced elsewhere in the infected organism. The resultant fused
o a novel target cell (right) lacking YR but carrying XR.a resul
ely) bupplication to subconfluent cultures of fresh indicator
ells (either 293T cells or CD4/CXCR-4-expressing 293T
252 RAPID COMMUNICATIONcells) in a 12-well (4.9 cm2) multidish. CD4/CXCR-4-express-
ing 293T indicator cells were generated by stable expres-
sion of CD4 (from plGRE-CD4 (9)) plus CXCR-4 (from pBA-
BE.fusin (12)) in 293T cells. Seventy-two hours later, cell
lysates were prepared and total luciferase activities per
culture measured using standard procedures.
Inhibition of Particle Fusion. Culture supernatants from
SIM-2 plus SIM-4 (1:1) hybridoma cells (19), releasing
antibodies reacting with CD4 and able to inhibit infection
by pNL4-3 HIV, or from H-EGFR-RI hybridoma cells (20),
releasing antibodies against human epidermal growth
factor receptor, which are thus irrelevant in this context,
were added to the mixtures of target and fusion particles
during the incubation period before application to indi-
cator cells. The final concentration of mouse antibody
was approx 1 mg/ml.
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Note added in proof. Alternative interpretations of the data pre-
sented could be (1) fusion particles independently fuse with target
cells, thus depositing HIV Env or VSV-G on the cell surface, which now
serve as receptors for the respective cellular receptors on target
particles. This is unlikely in the case of VSV-G, which fuses with, and
would be deposited on, the endosomal membrane. (2) Fusion between
the membranes of target and fusion particles may not reach completion
in suspension outwith the cell. Alternatively, preformed complexes
between fusion-competent target and fusion particles, which have not
yet completed fusion, may initially fuse with the target cell membrane,
mediated by HIV Env or VSV-G (in this latter case, fusion would be in
the endosome), and subsequently, fusion with the target particle mem-
brane would go to completion. The data do not support or rule out this
possibility. However, this consideration does not detract from the im-
plications concerning host-range extension and potential application
as vaccine strategy.
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